Arax Advisory Partners Sells 19,892 Shares of IQVIA Holdings Inc. $IQV

Arax Advisory Partners trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 71.2% in the 4th quarter, HoldingsChannel reports. The firm owned 8,055 shares of the medical research company’s stock after selling 19,892 shares during the quarter. Arax Advisory Partners’ holdings in IQVIA were worth $1,816,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Eagle Rock Investment Company LLC raised its holdings in shares of IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after acquiring an additional 11,657 shares in the last quarter. EDENTREE ASSET MANAGEMENT Ltd purchased a new stake in shares of IQVIA during the 3rd quarter worth approximately $7,368,000. AMG National Trust Bank purchased a new stake in IQVIA during the 3rd quarter valued at $3,713,000. Citigroup Inc. raised its holdings in IQVIA by 108.2% during the 3rd quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after buying an additional 475,557 shares during the period. Finally, Dana Investment Advisors Inc. raised its holdings in IQVIA by 18.4% during the 3rd quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock valued at $30,401,000 after buying an additional 24,854 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent research reports. Truist Financial decreased their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Mizuho set a $215.00 price target on IQVIA in a report on Monday, February 23rd. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a report on Friday, March 6th. Morgan Stanley set a $225.00 price target on IQVIA in a report on Thursday, May 7th. Finally, Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Buy” and an average target price of $224.13.

IQVIA Stock Performance

IQV stock opened at $178.07 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business’s fifty day simple moving average is $173.65 and its two-hundred day simple moving average is $193.06. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The firm has a market cap of $29.72 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 1.56 and a beta of 1.21.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the firm posted $2.70 earnings per share. The business’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.